Pfizer COVID-19 Vaccine Data Unlikely to Come Before Election
Crucial coronavirus vaccine data expected from Pfizer this week now appears unlikely to come before the U.S. election on Nov. 3.
On a call with investors Tuesday, Pfizer CEO Albert Bourla said that the company doesn’t anticipate making any announcement on its trial until about a week after the data and safety monitoring board conducts its review of the company’s phase three vaccine trial. The board, which will assess whether its trial with German drugmaker BioNTech has been successful, has not conducted an interim efficacy analysis yet, Pfizer said.
“In case of a conclusive readout … we will inform the public as soon as we complete the necessary administrative work, which we estimate to be completed within one week from the time we know,” Bourla said on the call.
